GWO-TSANN CHUANGI-JUNG TSAITsau, Yong-KweiYong-KweiTsauMENG-YAO LU2021-01-132021-01-132015-121320-5358https://scholars.lib.ntu.edu.tw/handle/123456789/540539Deferasirox is a new oral iron chelating agent with several cases reporting renal adverse events in recent years. Our aim was to identify the incidence of deferasirox-related Fanconi syndrome (FS) and its risk factors.enFanconi syndrome; Thalassaemia; deferariox; hypophosphataemia; renal tubular acidosis[SDGs]SDG3creatinine; deferasirox; benzoic acid derivative; deferasirox; iron chelating agent; triazole derivative; Article; child; controlled study; creatinine blood level; disease association; drug dose reduction; drug safety; Fanconi renotubular syndrome; female; human; hypophosphatemia; incidence; kidney tubule acidosis; major clinical study; male; priority journal; retrospective study; school child; thalassemia; treatment duration; treatment withdrawal; adolescent; blood; blood transfusion; chemically induced; Fanconi Syndrome; hypophosphatemia; kidney tubule acidosis; preschool child; risk factor; Taiwan; thalassemia; university hospital; young adult; Acidosis, Renal Tubular; Adolescent; Benzoates; Blood Transfusion; Child; Child, Preschool; Fanconi Syndrome; Female; Hospitals, University; Humans; Hypophosphatemia; Incidence; Iron Chelating Agents; Male; Retrospective Studies; Risk Factors; Taiwan; Thalassemia; Triazoles; Young Adultjournal article10.1111/nep.1252326016559WOS:000364647400009